UC San Francisco Cell Therapy Raises Hope for Severe Human Forms
Epilepsy that does not respond to drugs can be halted in adult mice by transplanting a specific type of cell into the brain, UC San Francisco researchers have discovered, raising hope that a similar treatment might work in severe forms of human epilepsy.
UCSF scientists controlled seizures in epileptic mice with a one-time transplantation of medial ganglionic eminence (MGE) cells, which inhibit signaling in overactive nerve circuits, into the hippocampus, a brain region associated with seizures, as well as with learning and memory. Other researchers had previously used different cell types in rodent cell transplantation experiments and failed to stop seizures.
Cell therapy has become an active focus of epilepsy research, in part because current medications, even when effective, only control symptoms and not underlying causes of the disease, according to Scott C. Baraban, PhD, who holds the William K. Bowes Jr. Endowed Chair in Neuroscience Research at UCSF and led the new study. In many types of epilepsy, he said, current drugs have no therapeutic value at all.
“Our results are an encouraging step toward using inhibitory neurons for cell transplantation in adults with severe forms of epilepsy,” Baraban said. “This procedure offers the possibility of controlling seizures and rescuing cognitive deficits in these patients.”
The findings, which are the first ever to report stopping seizures in mouse models of adult human epilepsy, will be published online May 5 in the journal Nature Neuroscience.
During epileptic seizures, extreme muscle contractions and, often, a loss of consciousness can cause seizure sufferers to lose control, fall and sometimes be seriously injured. The unseen malfunction behind these effects is the abnormal firing of many excitatory nerve cells in the brain at the same time.
In the UCSF study, the transplanted inhibitory cells quenched this synchronous, nerve-signaling firestorm, eliminating seizures in half of the treated mice and dramatically reducing the number of spontaneous seizures in the rest. Robert Hunt, PhD, a postdoctoral fellow in the Baraban lab, guided many of the key experiments.
In another encouraging step, UCSF researchers reported May 2 that they found a way to reliably generate human MGE-like cells in the laboratory, and that, when transplanted into healthy mice,the cells similarly spun off functional inhibitory nerve cells. That research can be found online in the journal Cell Stem Cell.
In many forms of epilepsy, loss or malfunction of inhibitory nerve cells within the hippocampus plays a critical role. MGE cells are progenitor cells that form early within the embryo and are capable of generating mature inhibitory nerve cells called interneurons. In the Baraban-led UCSF study, the transplanted MGE cells from mouse embryos migrated and generated interneurons, in effect replacing the cells that fail in epilepsy. The new cells integrated into existing neural circuits in the mice, the researchers found.
“These cells migrate widely and integrate into the adult brain as new inhibitory neurons,” Baraban said. “This is the first report in a mouse model of adult epilepsy in which mice that already were having seizures stopped having seizures after treatment.”
The mouse model of disease that Baraban’s lab team worked with is meant to resemble a severe and typically drug-resistant form of human epilepsy called mesial temporal lobe epilepsy, in which seizures are thought to arise in the hippocampus. In contrast to transplants into the hippocampus, transplants into the amygdala, a brain region involved in memory and emotion, failed to halt seizure activity in this same mouse model, the researcher found.
The Latest Bing News on:
Epilepsy
- How Saudi investors found their way into an East Bay biotech targeting epilepsyon March 28, 2024 at 8:36 am
On way to tackling diseases of aging, Saudi investment group detours into East Bay biotech initially targeting a form of epilepsy ...
- Stoke Announces $125M Public Offering on Heels of Positive Data for Epilepsy Drugon March 28, 2024 at 8:18 am
Stoke Therapeutics plans to offer up more than 5.5 million shares of its common stock following positive Phase I/IIa data for its Dravet syndrome candidate.
- Is Posttraumatic Epilepsy Associated With Higher Dementia Risk?on March 28, 2024 at 5:39 am
Researchers examined the associations between posttraumatic epilepsy and dementia risk, as well as those between dementia risk and head injury or seizure/epilepsy alone.
- Seizure triggers: Identifying common triggers and ways to manage epilepsyon March 28, 2024 at 5:18 am
Recognise these triggers and implement these expert strategies to manage seizures if you or someone you know is living with epilepsy ...
- ‘Running into roadblocks’: N.B. family fights to get care for daughter with epilepsyon March 28, 2024 at 2:00 am
A New Brunswick family is struggling to get health care for their young daughter with epilepsy. They're now raising money to get treatment outside the province.
- Epilepsy and pregnancy: Managing epilepsy during pregnancy and potential effectson March 27, 2024 at 9:39 pm
Managing epilepsy during pregnancy requires careful planning, monitoring and coordination between the patient, obstetrician and neurologist to ensure the health of both the mother and the unborn child ...
- Epilepsy and the built environment: how architects can design inclusively for neurological conditionson March 27, 2024 at 11:41 am
But this almost universally accepted idea of a single trigger and response only highlights how little people know about epilepsy, says architectural designer and UCL postgraduate Jessie Buckle, even ...
- New epilepsy monitoring unit a 'game changer' for Manitobans: health ministeron March 26, 2024 at 5:14 pm
The province said two new units at Health Sciences Centre mean Manitobans living with medication-resistant epilepsy can access specialized care once again, after a similar facility was shut down in ...
- Epilepsy monitoring, recovery unit opens at Winnipeg’s HSCon March 26, 2024 at 1:46 pm
“The opening and expansion of the adult EMU is an important development for Manitobans living with epilepsy, and the opening of the new donor-funded Unit B5B will further enhance the care available at ...
- Shares in Bedford-based Stoke Therapeutics surge after encouraging results in studies of epilepsy medicineon March 26, 2024 at 10:51 am
The gene-based drug, whose laboratory name is STK-001, reduced the frequency of seizures by 43 percent to 85 percent in 34 patients who participated in four early stage studies.
The Latest Google Headlines on:
Epilepsy
[google_news title=”” keyword=”Epilepsy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Cell therapy
- Mustang Bio, Inc.: Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseaseson March 28, 2024 at 7:30 am
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth ...
- Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseaseson March 28, 2024 at 7:00 am
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune ...
- Robots and AI: The Future of Cell and Gene Therapy Manufacturingon March 27, 2024 at 1:00 pm
The elements needed to automate cell and gene therapy production are already available, they just need to be combined.
- Accelerating CAR T cell therapy: Lipid nanoparticles speed up manufacturingon March 26, 2024 at 5:00 pm
For patients with certain types of cancer, CAR T cell therapy has been nothing short of life changing. Developed in part by Carl June, Richard W. Vague Professor at Penn Medicine, and approved by the ...
- Study reveals inequities in access to CAR T cell therapyon March 26, 2024 at 1:40 pm
Hodgkin's Lymphoma (NHL) who are part of minority populations may not have equal access to cutting-edge CAR T cell therapies, according to a new analysis led by researchers from the Perelman School of ...
- Research unveils metabolic strategies to enhance CAR-T cell therapyon March 26, 2024 at 12:43 pm
While cancer remains one of the leading global causes of death, advancements in cancer therapies have significantly improved its manageability and potential for cure. Among these revolutionary cancer ...
- Mesoblast gains as FDA backs regulatory plans for cell therapyon March 26, 2024 at 3:53 am
Mesoblast (MESO) stock rises 22% after the FDA shows favorable views on the company's plans to gain U.S. approval for its cell tehrapy remestemcel-L. Read more here.
- Nkarta: NK Cell Therapy Advancement On Two Frontson March 25, 2024 at 1:03 pm
Nkarta had $250.9 million in cash as of December 31, 2023, to fund its operations into 2026. Despite this cash runway, a public offering of $240 million was expected to close in March 2024.
- What to Expect When Starting CAR T-Cell Therapy for Multiple Myelomaon March 24, 2024 at 5:00 pm
CAR T-cell therapy for multiple myeloma uses genetically engineered T cells to fight cancer. Learn about the preparation, procedure, potential side effects, and more.
- CAR T-Cell Therapy Helped Treat Glioblastoma, a Deadly Form of Brain Canceron March 19, 2024 at 9:11 am
A new generation of CAR T-cell therapy for the brain cancer glioblastoma succeeded in rapidly and significantly shrinking tumors in three patients. However, the effects tended to be transient.
The Latest Google Headlines on:
Cell therapy
[google_news title=”” keyword=”Cell therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]